<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02304198</url>
  </required_header>
  <id_info>
    <org_study_id>DA8159_PAH_EX</org_study_id>
    <nct_id>NCT02304198</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Long-term Safety of Udenafil in Patient With PAH</brief_title>
  <official_title>A Single-arm, Open-label, Extension Study to Evaluate the Long-term Safety of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the long-term safety of Udenafil in Patient with Pulmonary Arterial
      Hypertension(PAH). All the patients will receive Udenafil for 1-year(48-weeks).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary arterial Hypertension is characterized by a progressive incerease in pulmonary
      vascular resistance(PVR) leading to right ventricualar failure.

      Udenafil inhibits PDE 5, an enzyme that metabolizes cGMP, enhancing the cGMP mediated
      relaxation and growth inhibition of vascular smooth muscle cells, including those in the
      lung.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (Adverse Events, Physical Examination, Vital Sign, Electrocardiography, Laboratory test, etc)</measure>
    <time_frame>during 48-weeks</time_frame>
    <description>Adverse Events, Physical Examination, Vital Sign, Electrocardiography, Laboratory test, etc</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>6-MWD</measure>
    <time_frame>24, 48-week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BORG dyspnea score</measure>
    <time_frame>24, 48-week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHO class</measure>
    <time_frame>12, 24, 36, 48-week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical worsening(TTCW)</measure>
    <time_frame>during 48-weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-pro BNP</measure>
    <time_frame>24, 48-week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiography</measure>
    <time_frame>48-week</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Udenafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Udenafil 50mg tablet by mouth, every 12 hours for 1-year(48-weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Udenafil</intervention_name>
    <description>Udenafil 50mg tablet</description>
    <arm_group_label>Udenafil</arm_group_label>
    <other_name>Zydena</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who completed the initial study(DA8159_PAH_II), 12-week, double-blind,
             placebo-controlled trial

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duk-Kyung Kim, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sung-A Jang, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jun-Bin Park, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hyung-Kwan Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hyuk-Jae Jang, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hae-Ok Jung, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul St. Mary's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jung-Hyun Choi, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jae-Seung Lee, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kye-Hun Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jin-Ok Jeong, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungnam National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sang-Yeub Lee, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungbuk National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Gangnam-Gu, Irwon-Dong 50</state>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2014</study_first_submitted>
  <study_first_submitted_qc>November 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2014</study_first_posted>
  <last_update_submitted>April 15, 2016</last_update_submitted>
  <last_update_submitted_qc>April 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Udenafil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

